Feb 9 (Reuters) - MAUNA KEA TECHNOLOGIES SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES: CELLVIZIO COMBINED WITH ARTIFICIAL
INTELLIGENCE OUTPERFORMS STANDARD OF CARE FOR PANCREATIC CYST
DIAGNOSIS AND RISK STRATIFICATION
* NEW PEER-REVIEWED SYSTEMATIC META-ANALYSIS PUTS CELLVIZIO
DIAGNOSTIC ACCURACY AT 99%
* FURTHER PEER-REVIEWED CLINICAL EVIDENCE DEMONSTRATES
CELLVIZIO
ENHANCES DIAGNOSTIC ACCURACY AND PATIENT MANAGEMENT INCLUDING
SURGICAL DECISIONS
Source text for Eikon: ID:nBw4hpk8ca
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))